Dr Reddy's Labs gets 4 USFDA observations for Srikakulam facility
Advertisement
Hyderabad: Dr Reddy's Labs has announced that the United States Food & Drug Administration (USFDA) today completed a product-specific Pre-Approval Inspection (PAI) and a routine GMP inspection with four observations at the Company' formulations manufacturing facility in Srikakulam (FTO SEZ PU2).
The inspection was conducted from 8th May, 2023 to 12th May, 2023.
"We have been issued a Form 483 with four observations, which we will address within the stipulated timeline," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.